Tech Company Financing Transactions
Ribon Therapeutics Funding Round
Ribon Therapeutics, based in Cambridge, secured $65 million from Novartis Venture Fund, Celgene and Deerfield Capital.
Transaction Overview
Company Name
Announced On
1/7/2019
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds will be used to advance lead programs from the company's growing pipeline into clinical testing, including small molecule monoPARP inhibitors.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
35 Cambridgepark Dr.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Ribon is pioneering the development of first-in-class therapeutics targeting enzyme families that are activated under cellular stress conditions. We explore novel areas of disease biology and use our expertise in drug discovery to develop new and effective treatments for patients with high unmet need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Victoria Richon
Chief Financial Officer
Paul Brannelly
Chief Medical Officer
Sudha Parasuraman
Vice President
Heike Keilhack
Vice President
Kevin Kuntz
VP - Bus. Development
Edward Stewart
Browse more venture capital transactions:
Prev: 1/7/2019: Banyan Biomarkers venture capital transaction
Next: 1/7/2019: Boom Supersonic venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs